NasdaqGS:TNXPBiotechs
Tonix Pharmaceuticals Holding (TNXP) Q1 Loss Deepens To US$40.2 Million Reinforcing Bearish Narratives
Tonix Pharmaceuticals Holding (TNXP) opened 2026 with Q1 revenue of US$6.9 million and a reported loss of US$40.2 million, equal to EPS of US$2.93, against a share price of US$13.28. Over the past five quarters, revenue has moved from US$2.6 million in Q4 2024 to US$6.9 million in Q1 2026, while quarterly EPS over the same period has ranged between US$2.84 and US$9.77. This sets up a story where investors are weighing a growing top line against consistently loss making results and pressured...